The prognosis of glioblastoma (grade IV glioma), the most aggressive primary brain cancer, has remained relatively unchanged in the last two decades. Cancer immunotherapy has emerged as a viable treatment strategy for many aggressive solid tumors. Unfortunately, the immune-suppressive environment of glioblastoma has resulted in low patient response rates to cancer immunotherapies. This study aims to apply genomic tools to understand the basic mechanisms that drive immune suppression in glioblastoma. Overall, the research groups aims for a description of tumor-immune cell crosstalk in glioblastoma that will aid the design of therapeutic strategies based on the unique tumor-immune interactions of the disease.
Learn more about Professor McFaline-Figueroa here and on LinkedIn.
This project was funded through the Office of the Provost Grants Program for Junior Faculty who Contribute to the Diversity Goals of the University.